Back

Empagliflozin in patients with acute myocardial infarction.

29 August 2022 (14:37 - 14:56)
Organised by:
Congress Presentation Part of: Latest science in pharmacotherapy Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Harald Sourij

Medical University of Graz, Graz (Austria)

3 More presentations in this session

Presentation thumbnail
PHYSIC – Precision hypertension care, a randomized double-blind repeated cross-over trial
Professor J. Sundstrom (Uppsala, SE)
Slides Video
Presentation thumbnail
CLEVER-ACS - Everolimus in acute coronary syndromes.
Assistant Professor B. Stahli (Zurich, CH)
Slides Video
Presentation thumbnail
RIVER: Rivaroxaban for Valvular Heart Disease and Atrial Fibrillation.
Professor R. Lopes (Durham, US)
Slides Video

Access the full session

Session thumbnail
Latest science in pharmacotherapy
Video

The Event

Event poster

ESC Congress 2022

29 August 2022 14:37 CET
You may be interested in
thumbnail
Congress Presentation
The SGLT2 inhibitor empagliflozin in patients hospitalised for acute heart failure: a multinational randomised trial
25 August 2023
thumbnail
Congress Presentation
Baseline characteristics of patients enrolled in the EMPACT-MI trial
25 August 2023
thumbnail
Congress Presentation
Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction
1 September 2024
thumbnail
Congress Presentation
Cardiorenal effects and safety of initiation of empagliflozin after acute myocardial infarction
1 September 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources